ARCH Venture Partners X, LLC - 21 Jun 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
10%+ Owner
Signature
/s/ ARCH Venture Fund X, L.P., By: ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney in-fact
Issuer symbol
VERV
Transactions as of
21 Jun 2021
Net transactions value
$0
Form type
4
Filing time
23 Jun 2021, 16:29:06 UTC
Next filing
15 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock, par value $0.001 Conversion of derivative security +1,254,404 1,254,404 21 Jun 2021 ARCH Venture Fund X, L.P. F1, F3, F4
transaction VERV Common Stock, par value $0.001 Conversion of derivative security +1,254,405 1,254,405 21 Jun 2021 ARCH Venture Fund X Overage, L.P. F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Series A Convertible Preferred Stock Conversion of derivative security -7,107,024 -100% 0 21 Jun 2021 Common Stock 767,538 See Footnotes F1, F3, F4, F5
transaction VERV Series A Convertible Preferred Stock Conversion of derivative security -7,107,023 -100% 0 21 Jun 2021 Common Stock 767,538 See Footnotes F2, F3, F4, F5
transaction VERV Series A-2 Convertible Preferred Stock Conversion of derivative security -4,508,144 -100% 0 21 Jun 2021 Common Stock 486,866 See Footnotes F1, F3, F4, F5
transaction VERV Series A-2 Convertible Preferred Stock Conversion of derivative security -4,508,146 -100% 0 21 Jun 2021 Common Stock 486,867 See Footnotes F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

ARCH Venture Partners X, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F2 Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F3 ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
F4 The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering.
F5 The expiration date is not relevant to the conversion of these securities.